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Abstract
Background: Contrast enhanced ultrasound (CEUS) is an imaging technique which appeared on
the market around the year 2000 and proposed for the detection of liver metastases in
gastrointestinal cancer patients, a setting in which accurate staging plays a significant role in the
choice of treatment.
Methods:  A total of 109 patients with colorectal (n = 92) or gastric cancer prospectively
underwent computed tomography (CT) scan and conventional US evaluation followed by real time
CEUS. A diagnosis of metastases was made by CT or, for lesions not visibile at CT, the diagnosis
was achieved by histopathology or by a malignant behavior during follow-up.
Results: Of 109 patients, 65 were found to have metastases at presentation. CEUS improved
sensitivity in metastatic livers from 76.9% of patients (US) to 95.4% (p <0.01), while CT scan
reached 90.8% (p = n.s. vs CEUS, p < 0.01 vs US). CEUS and CT were more sensitive than US also
for detection of single lesions (87 with US, 122 with CEUS, 113 with CT). In 15 patients (13.8%),
CEUS revealed more metastases than CT, while CT revealed more metastases than CEUS in 9
patients (8.2%) (p = n.s.).
Conclusion: CEUS is more sensitive than conventional US in the detection of liver metastases and
could be usefully employed in the staging of patients with gastrointestinal cancer. Findings at CEUS
and CT appear to be complementary in achieving maximum sensitivity.
Background
The presence of liver metastases is an important determi-
nant of survival in colorectal cancer patients [1-4],
accounting for >50.000 deaths per year in the United
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States alone [2]. Prognosis is inversely related not only to
the presence of metastases but also the number and vol-
ume [3,4]. In recent years, it has become accepted that
hepatic metastasectomy, possibly repeated in cases of
recurrence, prolongs survival in comparison to even the
best medical treatment; therefore, surgery should be
offered to all patients not presenting extrahepatic spread,
who, depending upon co-morbidities and extent of the
parenchyma to be sacrified, are elegible for this procedure
[5,6]. Accurate and timely detection of hepatic metastases,
both at diagnosis and during follow-up, is, therefore, very
important on account of the critical therapeutic and prog-
nostic implications. Accurate assessment of the number,
size and site of metastases is mandatory to identify those
patients elegible for surgical treatment, or to forecast prog-
nosis in the event of other treatment modalities for unre-
sectable cases.
Pre-operative imaging techniques may fail to detect small
metastases i.e., <1–2 cm in size [7-11] which, when below
1 cm, may be overlooked, even at liver inspection and pal-
pation during surgery [7,9-13]. Of the various techniques
available in the detection of hepatic metastases, conven-
tional ultrasound (US) is slightly less sensitive than Com-
puted Tomography (CT) and significantly less sensitive
than magnetic resonance imaging (MRI) and Positron
Emission Tomography (PET) [14-21]. However, despite
these limitations, US is usually the first-line investigation
in the assessment of patients with gastrointestinal cancer
in Italy, due to its low cost, non-invasiveness, repeatability
and easy access. MRI and PET, and often CT, are, at least
in Italy, restricted to selected cases, due to their limited
availability and high costs. Thus, the introduction of new
techniques to increase the sensitivity of US in the detec-
tion of metastases would be a major advantage.
In 2002, new grey scale US techniques based on the har-
monic response to second generation contrast agents,
insonated with low acoustic pressure (low mechanical
index), became available. These techniques employ con-
trast microbubbles resonance and, avoiding contrast
destruction, allow real-time exploration of liver perfusion
[22].
As in MRI and CT, the use of contrast agents appeared to
enhance the sensitivity of US in the detection of liver
metastases, regardless of the primary tumor [11,14,16-
18,23]. So far, no study, to our knowledge, was carried out
to investigate the use of real time contrast-enhanced US
(CEUS) for liver staging selectively in gastrointestinal can-
cer patients.
Aim of the present investigation was to compare the accu-
racy of real-time CEUS, in the detection of hepatic metas-
tases from colorectal and gastric cancers, with that of two
commonly employed imaging techniques, namely con-
ventional B-mode US and CT.
Methods
A total of 120 patients, with recently diagnosed colorectal
or gastric cancer, referred to the two study Units for
abdominal US, were prospectively taken into considera-
tion for enrolment in the investigation. Patients were con-
secutive, as observed at both the US study Units. Exclusion
criteria were the finding of >4 metastases at conventional
US or controindication to CT. This limit in the number of
metastatic lesions was set in order to select patients in
whom a more accurate liver staging could, theoretically,
modify the treatment strategy. A total of 109 patients (64
males, 45 females, mean age 66 years, range 39–85) were
finally enrolled in the study.
The reference method for the diagnosis of metastatic
lesions was the typical appearance at CT. Lesions detected
only by US techniques or with an inconclusive CT appear-
ance had to be confirmed as being of metastatic nature by
inspection and/or pathological findings in the case of sur-
gical resection, or by percutaneous biopsy or by means of
multimodality imaging at follow-up (increase in size and/
or clear signs of a malignant nature, such as infiltration of
surrounding structures or progressive decrease in size/dis-
appearance under chemotherapy).
The site of the primary tumor was colon in 86 patients,
rectum in 6 and stomach in 17. Patients were enrolled
over a 24-months period and were observed at follow-up
for at least 6 months after CEUS examination; written
informed consent to enter the study was obtained from all
participants. CEUS studies were performed using com-
mercialy available US systems (Technos MPX® or Megas
GPX®, Esaote™, Genova, Italy) and 3.5-MHz transducers,
as described elsewhere [24]. US of the liver was first per-
formed with conventional B-mode. Metastases were iden-
tified according to conventional imaging criteria.
Thereafter, the contrast investigation was carried out fol-
lowing i.v. infusion of the US contrast agent in a cubital
vein. All patients received a bolus infusion of Sonovue®
(Bracco™, Milan, Italy); patients >70 kg received 4.8 ml of
contrast agent. Slim patients (<70 kg) in whom perfect
liver US explorability was possiblle, received 2.4 ml of
contrast. For all other patients <70 kg the choice between
2.4 and 4.8 ml of SonoVue was left to the operator, the
aim being to obtain all relevant diagnostic information
with the least amount of contrast, in order to reduce costs.
All contrast infusions were immediately followed by a 5
ml saline flush to clear the infusion line and to prevent a
decrease in the contrast agent flow in the arm veins. CEUS
was performed using contrast specific imaging software at
low acoustic power output (Mechanical Index < 0.1)
(CnTI® Esaote™, Genova, Italy), by one operator in Pia-BMC Cancer 2007, 7:171 http://www.biomedcentral.com/1471-2407/7/171
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cenza (F.G.) and by one of two operators in Bologna (F.P.,
M.M.). The same specific contrast detection imaging soft-
ware was present in both types of equipments and
employed throughout the study. The liver was assessed, in
all patients, in the arterial (10–35 sec), portal-venous
(40–120 sec) and late phases (>120 sec) following injec-
tion of SonoVue, according to published guidelines [22].
The liver was explored until a marked overall decrease in
contrast signal intensity occurred or complete disappear-
ance of contrast was reached, which, on average, occur 3–
6 minutes after contrast injection. Metastatic lesions were
considered those solid lesions showing contrast wash-out
in the portal phase, thus becoming markedly hypoechoic
or even anechoic in the late phase (Fig. 1, 2), regardless of
the type of arterial phase pattern, in accordance with
accepted criteria [22]. The number, site and size of metas-
tases, at baseline and contrast US, were recorded at the
time of US examination.
All patients also underwent contrast-enhanced CT, either
with 4-detector multislice CT (approximately two thirds
of the patients) or single-detector helical CT (the remain-
ing patients) performed within 4 weeks of the US exami-
nation (either before or after). All CT scans were
performed in the Radiology Units used by the referring
physician. The number, site and size of metastases were
recorded at the time of CT reporting.
US operators were blind to CT findings and viceversa,
whereas CEUS readers were fully aware of the findings of
conventional US exams, since the latter were carried out
immediately before CEUS examinations and by the same
operator.
The segmental distribution of the lesions was recorded in
all 3 modes. The agreement in lesion location was obvi-
ously consistent in conventional US and CEUS mode,
since the same operator performed both techniques, the
imaging approach was the same and the techniques were
performed practically at the same time. When, on the
other hand, a discrepancy was recorded in the location of
a lesion, between CT and US mode(s), the CT films and
US images/clips were retrospectively reviewed to assess
whether the same lesion was visualized by the various
modalities, but described in different segments or
whether the two imaging modalities had visualized two
distinct lesions.
The prevalence of benign lesions (e.g. hemangiomas, sim-
ple biliary cysts) was not within the scope of the present
study and is not reported herein.
The study was carried out in accordance with the Helsinki
declaration and was approved by the Ethics Committees
of the S. Orsola-Malpighi hospital in Bologna and Pietro
da Saliceto hospital, Piacenza, Italy, corresponding to the
two centers where CEUS was performed.
Statistical Analysis
Differences in the diagnostic accuracy of the various imag-
ing modalities were investigated in connection with: 1)
the rate of cases with metastatic disease; 2) the total
number of metastatic lesions detected. Analysis of vari-
ance (ANOVA) was performed to compare CT, conven-
tional B-mode and CEUS findings. Sensitivity in the
detection of liver metastatic cases, by the three imaging
modalities, was calculated on a patient basis and com-
pared using McNemar's test. In the detection analysis, a
Wilcoxon's matched pairs signed rank test was used to test
the difference in the number of lesions found by the two
imaging modalities. A "p" value < 0.05 was considered
statistically significant.
Results
Accuracy in identifying patients presenting metastatic liver 
disease
Of the 109 patients, 65 presented liver metastases and 44
did not. CEUS enhanced the sensitivity in the detection of
metastatic patients from 76.9% (B-mode) to 95.4%
(CEUS) (p < 0.001), while CT-scan reached 90.8% (p =
0.035 vs B-mode) (Table 1). A total of 47 patients were
correctly classified as metastatic by all 3 imaging tech-
niques. Of the remaining 18 metastatic patients, 9 (8.3%
of all patients) were diagnosed as metastatic both by
CEUS and CT, but not by B-mode US; CEUS revealed met-
astatic disease in 6 patients (5.5%), of whom 3 detected
also by B-mode conventional US, but not revealed as met-
astatic by CT (Table 2); CT revealed metastatic disease in
3 patients (2.8%) who, instead, had resulted negative at
CEUS (Table 2) and at baseline US (Table 2).
A few patients (<8% of total) showed suboptimal or poor
explorability of the liver at US imaging modalities accord-
ing to the US operator's subjective judgement. The cause
was either liver location (relatively high) and/or liver
echogenicity (bright/fatty liver). Two of these patients
belonged to the cases classified as false at CEUS. Indeed,
the negative predictive value for metastastic disease was
77.2% for baseline US, 88.0% for CT and 93.6% for CEUS
Identification of individual metastases and comparison 
between the various imaging techniques
CEUS significantly enhanced also the sensitivity in the
number of metastatic lesions detected in comparison to
conventional US. Baseline US revealed 87 metastases,
while CEUS identified 122 metastases and CT-scan 113
(Table 3). The total number of metastases detected was
132. Of these 132 lesions, the diagnosis was reached,
according to CT as reference method, in 113. The 19
lesions detected by CEUS, but not by CT were diagnosedBMC Cancer 2007, 7:171 http://www.biomedcentral.com/1471-2407/7/171
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as follows: 7 intraoperatively, 1 by liver biopsy and 11 by
increase in size during follow-up (a few following an ini-
tial decrease under chemotherapy). The smallest lesion
identified by CT was 8 mm in maximal diameter and 7
mm the smallest by CEUS and US.
Comparison between CEUS and conventional B-mode US
In 39 of the 65 metastatic patients (60%), the number of
focal metastatic lesions detected at CEUS and at conven-
tional B-mode US was identical. An increase was observed
in the number of detected lesions, on CEUS mode, com-
pared with conventional B-mode US in 26 out of the 65
patients. The mean number of lesions per metastatic
patient increased from 1.34 to 1.88 (p < 0.001 Wilcoxon's
matched pairs signed rank test). Conventional B mode US
did not reveal more lesions than CEUS in any of our
patients.
Comparison between CEUS and dual-phase CT
In 41 of the 65 metastatic patients (63%), the number of
lesions observed at CEUS and at dual-phase CT was iden-
tical. In the remaining 24 patients (37%), the number of
lesions varied. In 15/65 (23.1%) cases, 19 lesions were
seen at CEUS, but not at dual-phase CT, whereas in 9/65
(13.9%) patients, 10 lesions were seen at dual-phase CT
and missed at CEUS. The mean number of lesions in met-
astatic patients increased from 1.74 with CT to 1.88 with
CEUS (p = 0.219 Wilcoxon's matched pairs signed rank
test).
Comparison between dual-phase CT and conventional US
In 34/65 patients (52%), the number of lesions seen in
conventional B-mode US and at dual-phase CT was iden-
tical. In the remaining 31 patients (47.7%) with a differ-
ent number of lesions, more lesions were detected at dual-
phase CT than at conventional B-mode US in 24 (37%)
and more lesions at conventional B-mode US than at
dual-phase CT in 7 (10.8%) patients. The mean number
of lesions increased from 1.34 with conventional B-mode
US to 1.74 with CT (p < 0.002 Wilcoxon's matched pairs
signed rank test).
Discussion
The present study shows that real time low mechanical
index SonoVue-enhanced US and dual-phase helical CT
are considerably more sensitive than baseline US in the
detection of liver metastases from gastrointestinal cancers.
Similar data have been reported for liver metastases in
general, regardless of the primary site [17,25], and were,
herewith, demonstrated, for the first time, selectively, in
gastrointestinal cancers. From a clinical point of view, the
present results are very important, since an accurate stag-
ing may significantly change the therapeutic approach in
patients with liver metastases from gastrointestinal can-
cers.
Early and accurate detection of metastatic lesions in the
liver, or exclusion of liver involvement, is a prerequisite
for rational staging and follow-up of patients presenting
Table 1: Sensitivity of imaging in detection of metastases
Imaging modality Cases (Sensitivity%)
CEUS 62 (95.4%)
Conventional b-mode US 50 (76.9%)
Spiral CT 59 (90.8%)
Value of p calculated using Mc Nemar Test:
CEUS vs CT: p = 0.508
CEUS vs Conventional b-mode US: p <0.001
CEUS vs CT: p = 0.035
CEUS, contrast enhanced ultrasonography; CT, computed 
tomography. Total number of case-patients with liver metastases = 
65.













- (44) - (44) - (44)
Patients 
(n)1
+ (47) + (47) + (47)
Patients 
(n)2
+ (9) + (9) - (9)
+ * -- Surgery
+ * -- Surgery
-+  §+ # Surgery
-+   § + # Biopsy
-+   §+  # M R I
-+   § - MRI
-+   § - F-up
-+   § - F-up
+ * -- F-up
CEUS, contrast enhanced ultrasonography; CT = computed 
tomography.
1 A total of 44 patients were negative (-) for metastases with all 
imaging techniques, while 47 were positive (+) showing the same 
lesions with all techniques (first two lines). Remaining lines refer to 
patients in whom imaging findings showed a discrepancy in 
classifying them as metastatic.
2 in 9 patients CT and CEUS were concordant, being more 
sensitive than conventional US. In the remaining other 9 patients a 
discordance was reported among the three techniques. Each line 
provides information about a single patient. Since in these 9 
patients, CT and CEUS findings were not consistent, confirmation 
of the results was obtained by a further reference modality, as 
specified in the right column (MRI = Magnetic Resonance Imaging, 
F-up = frank progressive metastatic pattern during follow-up, 
Surgery = intraoperative or pathologic confirmation at the time of 
laparotomy for metastasis resection).
* patients with liver metastasis at CT, but negative with other 
techniques.
§ patients positive at CEUS and negative at CT.
# patients positive at both conventional US and CEUS and negative 
at CT.BMC Cancer 2007, 7:171 http://www.biomedcentral.com/1471-2407/7/171
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Comparison of CT (left column) and contrast enhanced US (CEUS) (right column) appearance of liver metastases in the  venous-late phases of portal perfusion Figure 1
Comparison of CT (left column) and contrast enhanced US (CEUS) (right column) appearance of liver metastases in the 
venous-late phases of portal perfusion. In the upper row a concordance is shown in the detections of a subcapsular metatasis 
localized in liver segment 7. Metastasis appears hypodense at CT and hypoechoic at CEUS (continuous-line arrows). In the 
middle and lower rows, two cases of discordance between CT and CEUS are shown. In the middle row the tiny subcapsular 
metastasis (dashed-line arrow) was detected by US, but not by CT. The metastastic nature of the lesion was confirmed intra-
operatively at the time of resection of the primary cancer plus metastasectomy. In the lower row, the metastatic lesion 
(dashed-line arrow), located anteriorly in segment 6, was identified by CT and missed by CEUS. The malignant nature of the 
lesion was confirmed at surgery.BMC Cancer 2007, 7:171 http://www.biomedcentral.com/1471-2407/7/171
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Table 3: Number of patients classified by each imaging technique, according to number of metastatic lesions detected (left column). 
Total of 65 patients presented metastases
Liver Metastases (n) Dual-Phase CT CEUS Conventional b-mode 
Ultrasound1
063 1 5
12 9 3 0 2 7
21 5 1 5 1 2





CEUS, contrast enhanced ultrasonography; CT, computed tomography.
1 For conventional b-mode US ≤ 4 lesions were allowed according to inclusion criteria.
Patterns of liver metastases at CEUS Figure 2
Patterns of liver metastases at CEUS. Lesions are indicted by white arrows. Upper row. In conventional B-mode ultrasound 
(left frame) the focal liver lesions is hardly visibile, showing a faint hyperechoic apperance. During the arterial phase (23 sec-
onds after contrast injection, central frame) the lesion shows a rim- like hyperechoic aspect, whereas it becomes practically 
anechoic during the late phase (160 seconds after injections, right frame), consistently with a metastasis from left colonic aden-
ocarcinoma. Lower row: in conventional B-mode ultrasound (left frame) this metastasis from rectal adenocarcinoma appears 
inhomogeneous, predominantly hypoechoic, whereas it becomes homogeneously hyperechoic during the arterial phase (32 
seconds after contrast injection, central frame) and washes contrast out in the late phase, becoming markedly hypoechoic (125 
seconds after injection, right frame).BMC Cancer 2007, 7:171 http://www.biomedcentral.com/1471-2407/7/171
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cancers with the potential risk of developing metastases in
the liver, as the first dissemination site. This is particularly
true for colorectal cancers, in which metastases can be effi-
ciently approached with surgical resection [26-29]. Opti-
mal management implies scrupulous assessment of the
feasibility of surgery, since patients with undetected
metastases left in situ derive no, or dubious, therapeutic
benefit from resection, indeed they risk complications
and poor quality of life, and might benefit more from
other treatment procedures.
Despite the fact that multidetector CT has been recom-
mended as the reference method to stage colorectal cancer
and diagnose liver metastasis [30], as well as or to moni-
tor patients for recurrent colorectal cancer [31], conven-
tional B-mode US is usually the first-step imaging
technique in the assessment of metastatic liver disease in
common clinical practice in various Italian institutions.
Dual-phase CT and MRI are often reserved for patients in
whom US has failed to show any lesions or is inconclusive
or in those in whom thorough assessment of chest and
abdomen is needed to plan subsequent treatment. Similar
approaches can be found in other European Countries,
such as The Netherlands, UK and France, as mentioned in
the recent literature [28,32,33]. In the latter studies,
reflecting clinical practice, the diagnosis of liver metastasis
was established by definite US features alone, or by CT or
by a combination of two. Furthermore, CT was recom-
mended, in guidelines published in year 2000, only in the
presence of clinical suspicion of possible recurrence [34].
Usually, no further assessment of the liver is required if US
detects disseminated liver involvement [35]. The
approach used in the present study seems, therefore, to
well reflect current clinical practice in many European
centers.
Accuracy of US, in the assessment of liver metastases, is
lower than that of dual-phase CT and MRI, with reported
values of 70–85% (76.9% in our series) in comparison to
reference imaging [15,36-38] and far less than gold stand-
ards, including intra-operative exploration [11]. False-
negative findings occur in as many as 15% of US studies.
Despite these shortcomings, US offers numerous advan-
tages: it is rapid, relatively inexpensive, easily available
and free from ionizing radiation. Disadvantages of US
include: the operator-dependent nature, difficulty related
to the detection of isoechoic hepatic lesions and those <1
cm in size, as well as limitations in the characterization of
hepatic lesions, which are not always metastatic, even in
cancer patients [14,15]. CEUS may overcome some of the
limitations of conventional B-mode, maintaining most of
the advantages of conventional US.
The overall sensitivity of CEUS, in the detection of liver
metastases, was comparable to that of spiral CT (Table 1)
[23,25], but several metastatic lesions were detected by
only one of the two techniques, as found when comparing
CT with MRI [39] or other acquisition protocols with CT
[8]. The burden of liver disease was not understaged, in
any of the patients, by CEUS mode compared with con-
ventional B mode. This is likely due to the sequential use
of conventional US and CEUS, with CEUS being focused
on all lesions detected at US, as well as, on the remaining
parenchyma. The fact that a few new lesions were not
detected at dual-phase CT, but were identified by CEUS, is
in keeping with previous reports [18,24,25] and may be
due to various reasons. Real-time modality, which allows
prolonged continuous exploration of the liver (2–3 min-
utes in the late phase), the high spatial resolution of US
with second harmonic imaging and the possibility to
repeat the procedure more than once, in the same session,
in the event of dubious lesions or difficult examinations,
may all contribute to the identification of small or subcap-
sular lesions, which could be missed by CT, especially if
not performed in specialized centers and with reliable
equipment.
Assessment of metastatic lesions at the time of exam
reporting and not on digitally recorded images, can be
seen as a potential limitation of the study. However, it
should not be forgotten that in most European Countries,
US examinations are performed directly by physicians,
who judge the presence of metastatic lesions during
dynamic visualization of the liver. Liver studies are per-
formed according to the needs and findings of each
patient and do not follow thoroughly standardized proto-
cols. Therefore, the present US study protocol reflects the
routine approach in the clinical setting, although this dif-
fers from that of CT, for which assessment of metastatic
lesions by multiple readers, blinded to each other, would
have represented a more accurate study modality.
Another limitation of the study is the inclusion of multi-
ple and different CT scanners. The use of a single type of
top class equipment, with a larger number of detectors
would probably have reduced the number of false nega-
tive results of CT in comparison to US modalities, but
would have referred to conditions often different from
everyday clinical practice, which the study protocol
attempted to resemble as closely as possible.
Since the present data confirm, also for gastrointestinal
cancers, the results of previous studies on the detection of
liver metastases from neoplasms of various origin [23,25],
CEUS of the liver could be recommended as an alternative
to CT or MRI in cases presenting controindications for
these techniques. Additionally CEUS may be used in asso-
ciation with CT, MRI or CT/PET in patients in whom fail-
ure to achieve accurate staging could result in not effectingBMC Cancer 2007, 7:171 http://www.biomedcentral.com/1471-2407/7/171
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adequate treatment or in whom most reliable prognostic
findings are highly desireable [39-41].
Agreement has not yet been reached, concerning the valid-
ity and effectiveness of follow-up after primary gastroin-
testinal cancer resection or metastasectomy [42].
However, the improvement in the results of liver surgery,
combined with chemotherapy and possibly with other
treatment modalities, such as radiofrequency ablation,
suggests that a follow-up program with sensitive imaging
techniques, leading to the early detection of recurrences,
may theoretically result in further improvement in the
survival rate [43]. In the post-treatment follow-up setting,
choice of which liver imaging technique should be per-
formed remains a matter of debate, since, once again,
costs, exposure to radiations and availability of resources
need to be taken into account, all of which are much
greater than when performed, only once, at staging. To
date, there is no reliable evidence, that a surveillance pro-
gram, with imaging modalities, is cost effective in colorec-
tal cancer patients [42]. Some oncologic guidelines
recommend post-treatment CT only in the presence of
clinical suspicion of recurrent disease [34], but in the cur-
rent practice this behavior varies considerably. Some
oncologists follow these guidelines, whereas others rec-
ommend conventional US once every 6 months and oth-
ers add, or perform only CT every 1 or 2 years [42].
Limitations to a more frequent use of CT, despite being
considered a more accurate technique, from a mere imag-
ing view-point [30], derive from costs, hazards related to
ionizing radiations and to the use of iodine contrast
agents as well as limited availability of resources in the fol-
low-up setting. For these reasons, therefore, MRI and PET
are poor candidates for periodic follow-up of cancer
patients. CEUS, on the other hand, shows significantly
better accuracy than conventional B-mode US, while pre-
senting several of the advantages of US, namely: a) no of
exposure to ionizing radiations; b) limited hazards related
to the use of contrast agents, the severe adverse events
ratio being extremely low [44]; c) low cost, even with the
use of contrast agents; d) possibility of acquiring addi-
tional information from preliminary conventional B-
mode US; e) theoretical widespread availability, since it
can be installed in most US instruments. This new tech-
nique, therefore, appears to be an ideal candidate in the
follow-up of patients not presenting liver metastases or
following liver resection for primary gastrointestinal can-
cer, at least of colorectal origin. Randomized prospective
studies are needed to confirm these findings.
Conclusion
In conclusion CEUS is more sensitive than conventional
US in the detection of liver metastases and could be use-
fully employed in the staging of patients with gastrointes-
tinal cancer. Findings with CEUS and helical CT, with 1–
4 detectors, appear comparable for overall sensitivity, but
are not exactly superimposable in the identification of
individual metastases. Thus, the two techniques could be
considered complementary in those cases in which high-
est global sensitivity is required. Additionally, CEUS
appears to have the potential to become the reference
technique, in daily practice, for the early detection of
metastastatic liver disease, at least in all those instances in
which, at present, only an US scan is prescribed to moni-
tor gastrointestinal cancer patients, without known liver
involvement.
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